{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:13:51Z","timestamp":1783646031139,"version":"3.55.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.cca.2026.121052","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T22:49:44Z","timestamp":1777762184000},"page":"121052","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Exploring the role of circulating glial fibrillary acidic protein and neurofilament light chain in myasthenia gravis"],"prefix":"10.1016","volume":"590","author":[{"given":"Caterina Maria","family":"Gambino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Agnello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Scazzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Tamburello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Masucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Vassallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Di Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Brighina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Ciaccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2026.121052_bb0005","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1474-4422(21)00357-4","article-title":"Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders","volume":"21","author":"Huijbers","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.cca.2026.121052_bb0010","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.cca.2026.121052_bb0015","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.12688\/f1000research.8206.1","article-title":"Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms","volume":"5","author":"Phillips","year":"2016","journal-title":"F1000Research"},{"key":"10.1016\/j.cca.2026.121052_bb0020","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1474-4422(21)00297-0","article-title":"Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders","volume":"21","author":"Punga","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.cca.2026.121052_bb0025","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.cca.2026.121052_bb0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/bs.irn.2025.04.034","article-title":"Diagnosis of MG and differential diagnoses","volume":"183","author":"Habib","year":"2025","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.cca.2026.121052_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2025.578718","article-title":"Clinical utility of autoantibodies in the diagnosis and management of myasthenia gravis","volume":"407","author":"El-Wahsh","year":"2025","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.cca.2026.121052_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2025.103875","article-title":"Myasthenia gravis with antibodies against the AChR, current knowledge on pathophysiology and an update on treatment strategies with special focus on targeting plasma cells","volume":"24","author":"Man\u00e9-Damas","year":"2025","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.cca.2026.121052_bb0045","first-page":"205","article-title":"Blood and digital biomarkers in MG","volume":"182","author":"Bhandage","year":"2025","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.cca.2026.121052_bb0050","article-title":"On the road to blood biomarkers in myasthenia gravis (MG): beyond clinical scales","author":"Bhandage","year":"2025","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.cca.2026.121052_bb0055","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.tins.2015.04.003","article-title":"Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker","volume":"38","author":"Yang","year":"2015","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.cca.2026.121052_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108624","article-title":"Serum glial fibrillary acidic protein is a body fluid biomarker: a valuable prognostic for neurological disease \u2013 a systematic review","volume":"107","author":"Heimfarth","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.cca.2026.121052_bb0065","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41582-021-00616-3","article-title":"Blood GFAP as an emerging biomarker in brain and spinal cord disorders","volume":"18","author":"Abdelhak","year":"2022","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.cca.2026.121052_bb0070","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0022-510X(99)00205-1","article-title":"Does myasthenia gravis affect the brain?","volume":"170","author":"Keesey","year":"1999","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.cca.2026.121052_bb0075","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcac018","article-title":"Structural and functional brain alterations in patients with myasthenia gravis","volume":"4","author":"Klaus","year":"2022","journal-title":"Brain Commun."},{"key":"10.1016\/j.cca.2026.121052_bb0080","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.neuroscience.2020.03.009","article-title":"Antibodies and receptors: from neuromuscular junction to central nervous system","volume":"439","author":"Vincent","year":"2020","journal-title":"Neuroscience"},{"key":"10.1016\/j.cca.2026.121052_bb0085","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1515\/dx-2025-0042","article-title":"Exploring the role of glial fibrillary acid protein and neurofilament light chains in patients with hereditary transthyretin amyloidosis with polyneuropathy","volume":"13","author":"Gambino","year":"2025","journal-title":"Diagnosis"},{"key":"10.1016\/j.cca.2026.121052_bb0090","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","article-title":"Neurofilament light chain as a biomarker in neurological disorders","volume":"90","author":"Gaetani","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.cca.2026.121052_bb0095","doi-asserted-by":"crossref","first-page":"960","DOI":"10.3390\/brainsci14100960","article-title":"Cerebrospinal fluid neurofilaments light-chain differentiate patients affected by Alzheimer\u2019s disease with different rate of progression (RoP): a preliminary study","volume":"14","author":"Blandino","year":"2024","journal-title":"Brain Sci."},{"key":"10.1016\/j.cca.2026.121052_bb0100","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40001-023-01631-4","article-title":"Prediction of clinical progression in nervous system diseases: plasma glial fibrillary acidic protein (GFAP)","volume":"29","author":"Zheng","year":"2024","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.cca.2026.121052_bb0105","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/brain\/awae035","article-title":"Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles","volume":"147","author":"S\u00e1nchez-Juan","year":"2024","journal-title":"Brain"},{"key":"10.1016\/j.cca.2026.121052_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2025.120248","article-title":"The value of serum glial fibrillary acidic protein as a biomarker of astrogliosis in different neurological diseases","volume":"572","author":"Agnello","year":"2025","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cca.2026.121052_bb0115","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of Myasthenia Gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.cca.2026.121052_bb0120","article-title":"Myasthenia gravis: a review of available treatment approaches","volume":"2011","author":"Gilhus","year":"2011","journal-title":"Autoimmune Dis."},{"key":"10.1016\/j.cca.2026.121052_bb0125","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.cca.2026.121052_bb0130","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cccn.2005.05.035","article-title":"A sensitive non-isotopic assay for acetylcholine receptor autoantibodies","volume":"364","author":"Hewer","year":"2006","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cca.2026.121052_bb0135","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1515\/cclm-2025-0093","article-title":"Establishing sex- and age-related reference intervals of serum glial fibrillary acid protein measured by the fully automated Lumipulse system","volume":"63","author":"Agnello","year":"2025","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.cca.2026.121052_bb0140","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation","volume":"21","author":"Teunissen","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.cca.2026.121052_bb0145","article-title":"Glial fibrillary acidic protein in blood as a disease biomarker of neuromyelitis optica spectrum disorders","volume":"13","author":"Kim","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.cca.2026.121052_bb0150","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.ibneur.2025.04.016","article-title":"Bridging neuro-biomarkers and MR imaging: the synergistic role of glial fibrillary acidic protein in early CNS disease diagnosis","volume":"18","author":"Ghaderian","year":"2025","journal-title":"IBRO Neurosci. Rep."},{"key":"10.1016\/j.cca.2026.121052_bb0155","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1093\/clinchem\/hvaf120","article-title":"Age-specific control and Alzheimer disease reference curves and z-scores for glial fibrillary acidic protein in blood","volume":"71","author":"Halbgebauer","year":"2025","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cca.2026.121052_bb0160","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1515\/cclm-2025-0870","article-title":"Validation of a plasma GFAP immunoassay and establishment of age-related reference values: bridging analytical performance and routine implementation","volume":"63","author":"Arslan","year":"2025","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.cca.2026.121052_bb0165","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1515\/cclm-2022-0646","article-title":"Serum GFAP - reference interval and preanalytical properties in Danish adults","volume":"60","author":"Tybirk","year":"2022","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.cca.2026.121052_bb0170","doi-asserted-by":"crossref","first-page":"e1531","DOI":"10.1212\/WNL.0000000000207706","article-title":"Demographic and clinical characteristics associated with serum GFAP levels in an ethnically diverse cohort","volume":"101","author":"Gonzales","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.cca.2026.121052_bb0175","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","article-title":"Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer Disease continuum","volume":"78","author":"Benedet","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.cca.2026.121052_bb0180","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1136\/jnnp-2017-316583","article-title":"Clinical and immunological characteristics of the spectrum of GFAP autoimmunity: a case series of 22 patients","volume":"89","author":"Iorio","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.cca.2026.121052_bb0185","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.3389\/fimmu.2018.02802","article-title":"Autoimmune glial fibrillary acidic protein astrocytopathy: a review of the literature","volume":"9","author":"Shan","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cca.2026.121052_bb0190","doi-asserted-by":"crossref","DOI":"10.1111\/ene.70102","article-title":"A comparative study of 141 glial fibrillary acidic protein Immunoglobulin G positive cases","volume":"32","author":"Zhang","year":"2025","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.cca.2026.121052_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2025.103476","article-title":"Calprotectin and neurofilament serum levels correlate with treatment response in myasthenia gravis under intensified therapy-A pilot study","volume":"157","author":"Stascheit","year":"2025","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.cca.2026.121052_bb0200","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2025.1652698","article-title":"Serum neurofilament light chain levels in myasthenia gravis patients with and without symptoms","volume":"12","author":"Lv","year":"2025","journal-title":"Front. Med."},{"key":"10.1016\/j.cca.2026.121052_bb0205","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.1056322","article-title":"Serum neurofilament light chain in myasthenia gravis subgroups: an exploratory cohort and case-control study","volume":"13","author":"Stascheit","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.cca.2026.121052_bb0210","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/13872877251362496","article-title":"Plasma glial fibrillary acidic protein and neurological diseases: a bidirectional mendelian randomization study","volume":"107","author":"Jiang","year":"2025","journal-title":"J. Alzheimer\u2019s Dis"},{"key":"10.1016\/j.cca.2026.121052_bb0215","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12865-025-00735-2","article-title":"Clinical applications and diagnostic research of GFAP and NfL in MS and NMOSD: a meta-analysis","volume":"26","author":"Lin","year":"2025","journal-title":"BMC Immunol."},{"key":"10.1016\/j.cca.2026.121052_bb0220","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3390\/ijms26010185","article-title":"The role of GFAP in post-mortem analysis of traumatic brain injury: a systematic review","volume":"26","author":"Sacco","year":"2024","journal-title":"Int. J. Mol. Sci."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126002342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126002342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:29:54Z","timestamp":1783643394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898126002342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":44,"alternative-id":["S0009898126002342"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2026.121052","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring the role of circulating glial fibrillary acidic protein and neurofilament light chain in myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2026.121052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"121052"}}